CY1114535T1 - Ρετινοειδη παραγωγα με αντιαγγειογονικες, αντιογκικες και προαποπτωτικες δραστικοτητες - Google Patents

Ρετινοειδη παραγωγα με αντιαγγειογονικες, αντιογκικες και προαποπτωτικες δραστικοτητες

Info

Publication number
CY1114535T1
CY1114535T1 CY20111100294T CY111100294T CY1114535T1 CY 1114535 T1 CY1114535 T1 CY 1114535T1 CY 20111100294 T CY20111100294 T CY 20111100294T CY 111100294 T CY111100294 T CY 111100294T CY 1114535 T1 CY1114535 T1 CY 1114535T1
Authority
CY
Cyprus
Prior art keywords
antiogenic
angiogenic
diagnostic activities
retinoid derivative
retinoid
Prior art date
Application number
CY20111100294T
Other languages
Greek (el)
English (en)
Inventor
L Merlini
S Dallavalle
Sergio Penco
G Giannini
C Pisano
L Vesci
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11455702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114535(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of CY1114535T1 publication Critical patent/CY1114535T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Indole Compounds (AREA)
CY20111100294T 2001-07-31 2011-03-16 Ρετινοειδη παραγωγα με αντιαγγειογονικες, αντιογκικες και προαποπτωτικες δραστικοτητες CY1114535T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000464A ITRM20010464A1 (it) 2001-07-31 2001-07-31 Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
EP02760553A EP1412317B1 (en) 2001-07-31 2002-07-18 Retinoid derivatives with antiangiogenic, antitumor and proapoptotic activities

Publications (1)

Publication Number Publication Date
CY1114535T1 true CY1114535T1 (el) 2016-10-05

Family

ID=11455702

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100294T CY1114535T1 (el) 2001-07-31 2011-03-16 Ρετινοειδη παραγωγα με αντιαγγειογονικες, αντιογκικες και προαποπτωτικες δραστικοτητες

Country Status (19)

Country Link
US (2) US8101793B2 (enExample)
EP (1) EP1412317B1 (enExample)
JP (1) JP4463550B2 (enExample)
KR (1) KR100888466B1 (enExample)
CN (1) CN1279014C (enExample)
AT (1) ATE492526T1 (enExample)
AU (1) AU2002326144B2 (enExample)
BR (1) BR0211521A (enExample)
CA (1) CA2454532C (enExample)
CY (1) CY1114535T1 (enExample)
DE (1) DE60238683D1 (enExample)
DK (1) DK1412317T3 (enExample)
ES (1) ES2358097T3 (enExample)
HU (1) HU229308B1 (enExample)
IT (1) ITRM20010464A1 (enExample)
MX (1) MXPA04000877A (enExample)
PL (1) PL207530B1 (enExample)
PT (1) PT1412317E (enExample)
WO (1) WO2003011808A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
ITRM20010464A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
CA2468745A1 (en) 2001-11-30 2003-06-12 The Burnham Institute Induction of apoptosis in cancer cells
KR20040070254A (ko) * 2001-12-20 2004-08-06 휴먼 게놈 사이언시즈, 인코포레이티드 Ｔｒａｉｌ 수용체에 면역특이적으로 결합하는 항체
AP2413A (en) 2005-02-22 2012-06-01 Ranbaxy Lab Ltd 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease.
AU2006233810B2 (en) 2005-04-08 2011-02-17 Galderma Research & Development New method for the preparation of 6-(3-(1-adamantyl)-4-methoxphenyl)-2-naphthoic acid
FR2884248B1 (fr) * 2005-04-08 2007-05-18 Galderma Res & Dev Nouveau procede de preparation de l'acide 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoique
ITRM20050248A1 (it) * 2005-05-20 2006-11-21 Sigma Tau Ind Farmaceuti Uso acido adamantil metossidifenil propenoico per il trattamento di patologie cutanee.
KR101288376B1 (ko) 2005-06-28 2013-07-22 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 바이페닐 및 나프틸―페닐 하이드록삼산 유도체
WO2007037188A1 (ja) * 2005-09-27 2007-04-05 Sapporo Medical University 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
WO2007071605A1 (en) * 2005-12-19 2007-06-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. The use of st1898 for the treatment of restenosis
JP5054006B2 (ja) * 2006-06-23 2012-10-24 ロート製薬株式会社 ヒアルロン酸産生促進能を有する組成物
US20100330200A1 (en) * 2006-12-22 2010-12-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combination of a retinoid and a platinum anticancer agent
WO2010000784A1 (en) * 2008-07-03 2010-01-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of restenosis
TW201031402A (en) * 2008-12-24 2010-09-01 Sigma Tau Ind Farmaceuti New retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties
US9051548B2 (en) 2009-02-03 2015-06-09 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010106135A1 (en) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combined use for the treatment of ovarian carcinoma
EP2516396A1 (en) 2009-12-23 2012-10-31 Wayne State University Therapeutic compounds
HUE029687T2 (en) * 2011-09-19 2017-03-28 Sigma Tau Ind Farmaceuti New effective HDAC inhibitor thio derivatives and their use as medicaments
JP5757602B2 (ja) * 2012-05-11 2015-07-29 国立大学法人金沢大学 不斉選択性の切り替えが可能なクロマトグラフィー用充填剤
CN104496839B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
US11707442B2 (en) 2015-09-25 2023-07-25 The General Hospital Corporation Antibacterial and antifungal compounds
WO2017127306A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
EP3301085A1 (en) 2016-09-29 2018-04-04 Biogem S.Ca.R.L. Retinoid derivatives with antitumor activity
US11389414B2 (en) * 2017-04-27 2022-07-19 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
IT201900003343A1 (it) * 2019-03-07 2020-09-07 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
CN111956806B (zh) * 2020-09-03 2023-04-07 四川大学 一种药物载体、胶束、药剂及其制备方法和应用
IT202000029882A1 (it) * 2020-12-04 2022-06-04 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
IT202000029906A1 (it) * 2020-12-04 2022-06-04 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi.
WO2022229017A1 (en) 2021-04-27 2022-11-03 Biogem S.C.A R.L. Adamantyl retinoid derivative with anticancer activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676052B1 (fr) * 1991-05-02 1994-04-29 Cird Galderma Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique.
IL127946A0 (en) * 1996-07-08 2000-02-17 Cird Galderma Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
ITRM20010464A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
CA2468745A1 (en) * 2001-11-30 2003-06-12 The Burnham Institute Induction of apoptosis in cancer cells

Also Published As

Publication number Publication date
BR0211521A (pt) 2004-09-14
ITRM20010464A1 (it) 2003-01-31
HU229308B1 (en) 2013-10-28
AU2002326144B2 (en) 2008-04-10
ATE492526T1 (de) 2011-01-15
CN1279014C (zh) 2006-10-11
KR20040028968A (ko) 2004-04-03
ES2358097T3 (es) 2011-05-05
MXPA04000877A (es) 2004-06-03
US7449495B2 (en) 2008-11-11
US20040235757A1 (en) 2004-11-25
PL368412A1 (en) 2005-03-21
PT1412317E (pt) 2011-03-21
DK1412317T3 (da) 2011-03-28
JP2004536879A (ja) 2004-12-09
EP1412317B1 (en) 2010-12-22
US8101793B2 (en) 2012-01-24
US20080021088A1 (en) 2008-01-24
KR100888466B1 (ko) 2009-03-12
WO2003011808A1 (en) 2003-02-13
CN1537094A (zh) 2004-10-13
DE60238683D1 (de) 2011-02-03
PL207530B1 (pl) 2010-12-31
CA2454532C (en) 2011-01-25
EP1412317A1 (en) 2004-04-28
HUP0401604A2 (hu) 2004-12-28
ITRM20010464A0 (it) 2001-07-31
CA2454532A1 (en) 2003-02-13
JP4463550B2 (ja) 2010-05-19
HUP0401604A3 (en) 2006-01-30
HK1068868A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
CY1114535T1 (el) Ρετινοειδη παραγωγα με αντιαγγειογονικες, αντιογκικες και προαποπτωτικες δραστικοτητες
CY1107272T1 (el) Παραγωγο διαρυλ σουλφιδιου, αλας προσθηκης εξ αυτου και ανοσοκατασταλτικο
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
CY1106076T1 (el) Παραγωγα γλυκοπυρανοσυλοξυβενζυλο βενζολιου και ιατρικες συνθεσεις που πepιεχουν τα ιδια
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
BR0208338A (pt) Derivados de piridina
CY1111867T1 (el) Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη
FI943749A0 (fi) Taksaanijohdannaisten fosfono-oksimetyylieetterit
GT200000103A (es) Trifluorbutenos nematocidas.
EP1431275A4 (en) DIARYL ETHER DERIVATIVE, ITS ADDITIONAL SALT AND IMMUNOSUPPRESSEUR
EP1399414A4 (en) SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA
DK0842934T3 (da) 5-HT1F agonister
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
CY1110537T1 (el) Ενωσεις και μεθοδοι για την αγωγη της δυσλιπιδαιμιας
ATE476177T1 (de) Orale zubereitungen enthaltend cladribin
MY146098A (en) Oxazole derivatives of tetracyclines
ID25478A (id) Agonis 5-ht1f
MXPA02011234A (es) Nuevas bases de oxidacion 2,5-diaminopiridina utiles para el tinte de las fibras queratinicas.
DE60111614D1 (de) Taxan-derivate für die behandlung von krebs
YU83903A (sh) Farmaceutske kombinacije zasnovane na derivatima piridoindolona
PT1011329E (pt) Paclitaxeis de 7-metiltio-oxometilo e 7-metiltiodioxometilo
ATE478155T1 (de) Glycopeptidantibiotika
CY1110139T1 (el) Γλυκοπεπτιδικα αντιβιοτικα
DE69915688D1 (de) Benzonaphtyridin-1,8 derivate
DK0810223T3 (da) Adamantylsubstituerede oxindoler som farmaceutiske midler